Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

More gains for Nvidia, Amazon and other AI superstars propped up Wall Street on Monday. The S&P 500 rose 0.2% and pulled closer to its all-time high set last week, even though the majority of stocks ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health ...

The news comes as Kenvue maker Tylenol has been embroiled in litigation surrounding the alleged relationship between Tylenol ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...